TY - JOUR
T1 - A National Survey of Practice Patterns for Accepting Living Kidney Donors With Prior COVID-19
AU - Jan, Muhammad Y.
AU - Jawed, Areeba T.
AU - Barros, Nicolas
AU - Adebiyi, Oluwafisayo
AU - Diez, Alejandro
AU - Fridell, Jonathan A.
AU - Goggins, William C.
AU - Yaqub, Muhammad S.
AU - Anderson, Melissa D.
AU - Mujtaba, Muhammad A.
AU - Taber, Tim E.
AU - Mishler, Dennis P.
AU - Kumar, Vineeta
AU - Lentine, Krista L.
AU - Sharfuddin, Asif A.
N1 - Publisher Copyright:
© 2021 International Society of Nephrology
PY - 2021/8
Y1 - 2021/8
N2 - Introduction: A critical question facing transplant programs is whether, when, and how to safely accept living kidney donors (LKDs) who have recovered from COVID-19 infection. The purpose of the study is to understand current practices related to accepting these LKDs. Methods: We surveyed US transplant programs from 3 September through 3 November 2020. Center level and participant level responses were analyzed. Results: A total of 174 respondents from 115 unique centers responded, representing 59% of US LKD programs and 72.4% of 2019 and 72.5% of 2020 LKD volume (Organ Procurement and Transplantation Network-OPTN 2021). In all, 48.6% of responding centers had received inquiries from such LKDs, whereas 44.3% were currently evaluating. A total of 98 donors were in the evaluation phase, whereas 27.8% centers had approved 42 such donors to proceed with donation. A total of 50.8% of participants preferred to wait >3 months, and 91% would wait at least 1 month from onset of infection to LD surgery. The most common reason to exclude LDs was evidence of COVID-19−related AKI (59.8%) even if resolved, followed by COVID-19−related pneumonia (28.7%) and hospitalization (21.3%). The most common concern in accepting such donors was kidney health postdonation (59.2%), followed by risk of transmission to the recipient (55.7%), donor perioperative pulmonary risk (41.4%), and donor pulmonary risk in the future (29.9%). Conclusion: Practice patterns for acceptance of COVID-19−recovered LKDs showed considerable variability. Ongoing research and consensus building are needed to guide optimal practices to ensure safety of accepting such donors. Long-term close follow-up of such donors is warranted.
AB - Introduction: A critical question facing transplant programs is whether, when, and how to safely accept living kidney donors (LKDs) who have recovered from COVID-19 infection. The purpose of the study is to understand current practices related to accepting these LKDs. Methods: We surveyed US transplant programs from 3 September through 3 November 2020. Center level and participant level responses were analyzed. Results: A total of 174 respondents from 115 unique centers responded, representing 59% of US LKD programs and 72.4% of 2019 and 72.5% of 2020 LKD volume (Organ Procurement and Transplantation Network-OPTN 2021). In all, 48.6% of responding centers had received inquiries from such LKDs, whereas 44.3% were currently evaluating. A total of 98 donors were in the evaluation phase, whereas 27.8% centers had approved 42 such donors to proceed with donation. A total of 50.8% of participants preferred to wait >3 months, and 91% would wait at least 1 month from onset of infection to LD surgery. The most common reason to exclude LDs was evidence of COVID-19−related AKI (59.8%) even if resolved, followed by COVID-19−related pneumonia (28.7%) and hospitalization (21.3%). The most common concern in accepting such donors was kidney health postdonation (59.2%), followed by risk of transmission to the recipient (55.7%), donor perioperative pulmonary risk (41.4%), and donor pulmonary risk in the future (29.9%). Conclusion: Practice patterns for acceptance of COVID-19−recovered LKDs showed considerable variability. Ongoing research and consensus building are needed to guide optimal practices to ensure safety of accepting such donors. Long-term close follow-up of such donors is warranted.
KW - COVID-19
KW - kidney transplantation
KW - living kidney donation
KW - pandemic
KW - recovered living kidney donors
UR - http://www.scopus.com/inward/record.url?scp=85108061535&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85108061535&partnerID=8YFLogxK
U2 - 10.1016/j.ekir.2021.05.003
DO - 10.1016/j.ekir.2021.05.003
M3 - Article
AN - SCOPUS:85108061535
SN - 2468-0249
VL - 6
SP - 2066
EP - 2074
JO - Kidney International Reports
JF - Kidney International Reports
IS - 8
ER -